Postpartum Depression — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for postpartum depression. 23 active patents protecting 2 drugs from 2+ originators. First major cliff: 2034. Daily refresh.

2
Approved drugs
23
Active US patents
52/100
Avg vulnerability
$100M
Annual revenue covered

Originators in Postpartum Depression

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Biogen 15 patents Sage Therap 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating postpartum depression. Each bar = one year. Y-axis scaled to peak year (9 patents).

5
29
2
33
9
34
7
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zurzuvae
ZURANOLONE
 Biogen 15 48 $100M 2034-04-17
Zulresso
BREXANOLONE
 Sage Therap 8 55 — 2029-03-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11884696 Zurzuvae method of use 75 2037-08-23
11884696 Zurzuvae method of use 75 2037-08-23
11884696 Zurzuvae method of use 75 2037-08-23
10172871 Zurzuvae method of use 70 2034-04-17
10342810 Zurzuvae method of use 70 2034-04-17
10172871 Zurzuvae method of use 70 2034-04-17
10342810 Zurzuvae method of use 70 2034-04-17
10172871 Zurzuvae method of use 70 2034-04-17
10342810 Zurzuvae method of use 70 2034-04-17
10251894 Zulresso method of use 62 2033-11-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11236121 Zurzuvae composition of matter 12 2037-08-23
11236121 Zurzuvae composition of matter 12 2037-08-23
11236121 Zurzuvae composition of matter 12 2037-08-23
9512165 Zurzuvae composition of matter 12 2034-04-17
9512165 Zurzuvae composition of matter 12 2034-04-17
9512165 Zurzuvae composition of matter 12 2034-04-17
10322139 Zulresso formulation 42 2033-01-23
8410077 Zulresso formulation 55 2029-03-13
7635773 Zulresso formulation 55 2029-03-13
9750822 Zulresso formulation 55 2029-03-13

Related